|
5H-Pyrazolo[3,4-b]quinolin-5-one, 3-(2,2-dimethylpropyl)-1,2,4,6,7,8-hexahydro-4,7,7-trimethyl-4-phenyl-, (4S)- Suppliers list
|
| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
5H-Pyrazolo[3,4-b]quinolin-5-one, 3-(2,2-dimethylpropyl)-1,2,4,6,7,8-hexahydro-4,7,7-trimethyl-4-phenyl-, (4S)- manufacturers
- BRD3731
-
- $399.00
-
2026-07-27
- CAS:2056262-07-6
- Purity:
- Supply Ability: 10g
|
| | 5H-Pyrazolo[3,4-b]quinolin-5-one, 3-(2,2-dimethylpropyl)-1,2,4,6,7,8-hexahydro-4,7,7-trimethyl-4-phenyl-, (4S)- Basic information |
| Product Name: | 5H-Pyrazolo[3,4-b]quinolin-5-one, 3-(2,2-dimethylpropyl)-1,2,4,6,7,8-hexahydro-4,7,7-trimethyl-4-phenyl-, (4S)- | | Synonyms: | 5H-Pyrazolo[3,4-b]quinolin-5-one, 3-(2,2-dimethylpropyl)-1,2,4,6,7,8-hexahydro-4,7,7-trimethyl-4-phenyl-, (4S)-;(4S)-3-(2,2-dimethylpropyl)-4,7,7-trimethyl-4-phenyl-2,6,8,9-tetrahydropyrazolo[3,4-b]quinolin-5-one | | CAS: | 2056262-07-6 | | MF: | C24H31N3O | | MW: | 377.52 | | EINECS: | | | Product Categories: | | | Mol File: | 2056262-07-6.mol | ![5H-Pyrazolo[3,4-b]quinolin-5-one, 3-(2,2-dimethylpropyl)-1,2,4,6,7,8-hexahydro-4,7,7-trimethyl-4-phenyl-, (4S)- Structure](CAS/20210111/GIF/2056262-07-6.gif) |
| | 5H-Pyrazolo[3,4-b]quinolin-5-one, 3-(2,2-dimethylpropyl)-1,2,4,6,7,8-hexahydro-4,7,7-trimethyl-4-phenyl-, (4S)- Chemical Properties |
| Boiling point | 529.3±50.0 °C(Predicted) | | density | 1.15±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 50 mg/mL (132.44 mM; Need ultrasonic) | | form | Solid | | pka | 15.22±0.60(Predicted) | | color | Light yellow to yellow |
| | 5H-Pyrazolo[3,4-b]quinolin-5-one, 3-(2,2-dimethylpropyl)-1,2,4,6,7,8-hexahydro-4,7,7-trimethyl-4-phenyl-, (4S)- Usage And Synthesis |
| Uses | BRD3731 is a selective GSK3β inhibitor, with IC50s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. BRD3731 is potentail for the research of post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorders[1]. | | Biological Activity | BRD3731 is a selective GSK3β inhibitor, with IC50s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. BRD3731 is potentail for the research of post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorders[1].
BRD3731 is a GSK3β- selective inhibitor extracted from patent US20160375006A1, compound example 272[1].BRD3731 (1-10 μM; 24 hours) inhibits the phosphorylation of CRMP2 in SH-SY5Y cells[1].BRD3731 (20 μM; 24 hours) decreases β-catenin S33/37/T41 phosphorylation and induces β-catenin S675 phosphorylation in HL-60 cells[2].BRD3731 (10-20 μM; 7-10 days) impairs colony formation in TF-1 and increases colony forming ability in the MV4-11 cell line[2] | | IC 50 | GSK-3β: 15 nM (IC50); GSK-3α: 215 nM (IC50) | | References | [1]. Edward Scolnick, et al. Uses of paralog-selective inhibitors of gsk3 kinases. US20160375006A1. [2]. Wagner FF, et, al. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 Mar 7;10(431):eaam8460. |
| | 5H-Pyrazolo[3,4-b]quinolin-5-one, 3-(2,2-dimethylpropyl)-1,2,4,6,7,8-hexahydro-4,7,7-trimethyl-4-phenyl-, (4S)- Preparation Products And Raw materials |
|